copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
October 27 2025 - Novartis shares slip, Avidity soars after $12 billion . . . Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly board, Novo Nordisk boardMapLight goes public via $250M IPO to fund Cobenfy competitor
Novartis | Cafepharma Novartis has opened a 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad in the US state of California, as part of its $23bn investment in the country’s infrastructure up to 2030
Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' Fierce Biotech Thursday, November 20, 2025 - 11:01 am Novartis, Vas Narasimhan, Avidity Biosciences, M A, neuromuscular disease Novartis board Novo Nordisk set for high-stakes Alzheimer's studies that could reveal answers on GLP-1 benefit Yahoo Reuters
Avidity Biosciences | Cafepharma Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U S biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan
Xolair | Cafepharma Xolair, a 20-year-old asthma drug sold by Roche (ROG S) and Novartis (NOVN S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting
early breast cancer | Cafepharma Novartis is seeking approval for Kisqali as a treatment of early breast cancer, with an FDA application planned for submission by the end of this year
Novartis is returning to the Super Bowl in 2026 | Cafepharma After making a splash at Super Bowl LIX, Novartis is reportedly the first pharma brand to commit to the 2026 Big Game According to Ad Age, the brand has hired Publicis creative agency Fallon to create the spot Last year, the ad was created by Omnicom subsidiary Merkley and Partners, while Publicis’ N2 serves as the pharma giant’s media agency of record
Novartis ‘moving as fast as possible’ to fully manufacture key drugs in . . . In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production